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days of starting steroids when the serum CK had fallen to 
440 U I- ‘. After 1 week of treatment with steroids, she was 
able to mobilize and could wash and dress independently. 
Her swallowing improved such that she could take a soft 
solid diet. Her muscles were no longer tender and they had 
lost their woody feel. The apparent contractures of the 
upper limb resolved without formal physiotherapy. Treat- 
ment was converted to soluble prednisolone 30 mg daily. 
On Day 9, the serum CK was 188 U l- ’ and she was 
allowed home prior to commencing cyclical combination 
chemotherapy. She remained well on oral steroid therapy 
without clinical evidence of relapse. Unfortunately, she was 
found dead in bed at home just before her second cycle of 
chemotherapy was due, some 5 weeks after discharge from 
hospital. Permission for an autopsy was not granted. 
I+scussion 
We report a case of dermatomyositis temporally associated 
with diagnosing small cell carcinoma of the lung. A dra- 
matic clinical and biochemical response to corticosteroid 
therapy was demonstrated. 
In this case, the carcinoma was proven. Muscle biopsy 
was not performed to confirm dermatomyositis, but the 
diagnosis was supported by the clinical history and exami- 
nation findings supported by an elevated serum CK. Her 
muscles, rash and oesophageal dysmotility all displayed an 
impressive subjective and objective response to treatment. 
There was no relapse in her condition on converting from 
intravenous methylprednisolone to soluble prednisolone. In 
this individual, treatment with steroids yielded a dramatic 
and worthwhile improvement in her quality of life. 
Dermatomyositis in adults may be idiopathic, associated 
with collagen vascular disease or associated with neoplasia. 
Malignancy is noted in up to 30% of cases of adult 
dermatomyositis (3). Mortality rates of up to 50% have 
been reported due to the underlying malignancy and lack of 
response to therapy (4) Despite such therapeutic nihilism, 
we suggest that a trial of steroid therapy is warranted in 
patients with dermatomyositis, even if associated with a 
tumour with little chance of cure. The possible benefits in 
terms of enhanced quality of life are worthwhile. 
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Hypomagnesaemic tetany associated with repeated 
courses of intravenous tobramycin in a patient with 
cystic fibrosis 
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Regional Adult Cystic Fibrosis Centre, Seacroft Hospital, Leeds, U.K. 
Introduction We report the case of an adult patient with cystic fibrosis 
who developed hypomagnesaemic, hypocalcaemic tetany 
following repeated courses of intravenous tobramycin. 
Magnesium deficiency is usually secondary to either 
gastrointestinal or renal loss. The kidneys control the fine 
regulation of magnesium metabolism, re-absorption 
occurring mostly in the thick ascending limb of Henle 
(50-70%) and the proximal convoluted tubule (15-20%) (1). 
In normal homeostasis, urinary magnesium loss can be 
Intravenous aminoglycoside therapy may cause reversible 
renal tubular damage and symptomatic hypomagnesaemia. 
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TABLE 1. Details of intravenous antibiotic following referral 
to Seacroft Hospital, Cystic Fibrosis Unit 
Date Antibiotics received 
23/l l/934/12/93 
25/01/9416/02194 
18/02/946103/94 
21/03/9&31/03/94 
28104/9~1/05/94 
23105/94-1106194 
26/06/94-5/07/94 
Tobramycin, Piperacillin 
Tobramycin, Aztreonam, Piperacillin 
Tobramycin, Piperacillin 
Ticarcillin, Tazocin 
Colistin, Azlocillin 
Tobramycin, Ceftazidime 
Tobramycin, Ceftazidime 
reduced to less than 1 MEq day - ‘. Impairment of tubular 
re-absorption, however, can lead to rapid hypomagnesae- 
mia as magnesium cannot be mobilised selectively from 
either soft tissues or bone. Frequent courses of intravenous 
aminoglycosides may allow sufficient antibiotic accumula- 
tion in the kidney (the renal tissue half-life of tobramycin is 
about 74 h) to cause renal tubular damage and subsequent 
loss of magnesium. The renal damage is reversible but 
magnesium loss may persist for a prolonged period after 
cessation of aminoglycoside therapy. 
Case Report 
A 28-year-old woman was transferred to the Leeds 
Regional Adult Cystic Fibrosis Unit in November 1993. 
Full assessment showed severe cystic fibrosis, vital capacity 
(VC) 1.74 1, forced vital capacity (FVC) 1.51 1, forced 
expiratory volume (FEV,) 044 1, and 44, 39 and 13%, 
respectively, of predicted normal, mean nocturnal oxygen 
saturation of 94.9%, Northern Chest Radiograph Score 
16 (2) and Schwachman-Kulczycki score 45, (3). Sputum 
culture grew Cundida albicans, Staphylococcal aureus and 
Stenotrophomonus maltophilia. She had never received 
intravenous antibiotic therapy. Her treatment regimen was 
intensified by introducing vitamin A and D 2 capsules tds, 
vitamin E 200 mg od, nebulized tobramycin 160 mg bd, 
ferrous sulphate 200 mg bd and prednisolone 40 mg od. She 
continued her previous therapy of nebulized terbutaline 
5 mg bd, atrovent aerosol inhaler 4Opg tds, flucloxacillin 
500 mg tds, co-trimoxazole 960 mg bd, and Creon 25 000 
(daily total 20). Following a course of intravenous anti- 
biotic therapy, she reported subjective improvement, but 
showed only moderate change in her respiratory function 
with discharge values of VC 2.53 1, FVC 2.06 1 and FEV, 
0.65 1. In February 1994, she was referred to the supra- 
regional lung transplant centre. To maintain stability of 
lung function, repeated courses of antibiotic therapy were 
needed (Table 1). Choices of antibiotic were limited increas- 
ingly by highly resistant Stenotrophomonas maltophilia. 
Tobramycin dose was adjusted to achieve trough serum 
levels of less than 1 mg l- i and peak levels 30 min post- 
dose between 10 and 12 mg l- ‘. Tobramycin levels were 
assayed routinely at the third dose and weekly thereafter in 
each treatment course. Trough levels were uniformly 
< 1 mg 1 - ‘. Serum calcium was measured routinely at the 
beginning and end of each course of therapy, and values 
corrected for albumin levels ranged between 2.11 and 
2.48 mmol 1 - ’ (normal range 2.2-2.65). 
In June 1994, twice daily nebulized amphotericin B 10 mg 
was started as part of her pre-transplant regimen in 
response to persistent cultures of aspergillus from her 
sputum. On 15 July 1994, she was admitted with a further 
respiratory exacerbation. Treatment included intravenous 
tobramycin 160 mg tds and azlocillin 5 g tds. On the morn- 
ing of 19 July, she complained of an ‘odd tingling’ sensation 
affecting most of her body, and on the morning of 20 July, 
she developed acute carpo-pedal spasm and per&oral par- 
aesthesia. Chvostek’s sign was negative. Corrected serum 
calcium was 1.74 mmol 1~ ‘, serum albumin 29 g 1~ i and 
potassium 3.9 mmol 1~ i. Intermittent tetany persisted 
despite treatment with intravenous calcium gluconate 
2.5 mmol. Serum magnesium levels had not been measured 
previously but those taken on the morning of 20 July and 
available later the same day showed a concentration of 
0.29 mmol 1~ ’ (normal range 0.7-0.9 mmol l- ‘). Intra- 
venous tobramycin was stopped immediately and a 24 h 
infusion of 75 mmol magnesium sulphate commenced 
with rapid symptomatic relief. The following day, serum 
magnesium was 1.5 mmol 1 - ’ and corrected calcium was 
2.18mmoll-‘. 
She has since received nine courses of antibiotics with no 
recurrence of her symptoms, and continues on magnesium 
glycerophosphate 1 g tds. Serum magnesium concentra- 
tions varied between 0.2 and 0.72 mmol l- i for the first 
4 months after the event, suggesting a continued renal leak 
of magnesium. 
Discussion 
Hypomagnesaemia probably causes hypocalcaemia by 
interfering with cyclic AMP production in the parathyroid 
glands, leading to impaired parathyroid hormone (PTH) 
secretion (4). The inappropriately low PTH levels found in 
hypomagnesaemic, hypocalcaemic tetany return to normal 
following intravenous magnesium therapy (4). PTH biosyn- 
thesis is not impaired. Patients with cystic fibrosis are 
susceptible to hypomagnesaemia as a result of malabsorp- 
tion (magnesium binds to fat), malnutrition, secondary 
hyperaldosteronism, diabetes mellitus and treatment with 
aminoglycosideds (nephrotoxicity) (5-7), sodium contain- 
ing semi-synthetic penicillins (reduced sodium absorption 
and increased urinary magnesium excretion), or corticoster- 
oids (mineralocorticoid effect) (7). Aminoglycoside treat- 
ment does not cause chronic hypomagnesaemia (5), and 
published data show that serum magnesium levels in 
patients with cystic fibrosis are almost universally within 
the normal range, although showing an age-related fall 
(5,8). The latter may reflect the nephrotoxicity of the 
accumulative aminoglycoside load received by the older 
patients. Clinically evident hypomagnesaemia is rare (9) 
and always occurs during intravenous antibiotic treatment 
(7) as described in this paper. 
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We believe that our patient suffered hypomagnesaemic, 
hypocalcaemic tetany consequent upon renal damage after 
prolonged and recurrent courses of intravenous aminogly- 
cosides. She had received more than 28 000 mg tobramycin 
over a 6-month period. Other possible contributory factors 
were malabsorption (faecal fat 8.1 g day- ‘), and treatment 
with sodium containing semi-synthetic penicillins, mainten- 
ance prednisolone (total dosage exceeding 2800 mg) and 
nebulized amphotericin [intravenous amphotericin can 
cause both glomerular and tubular renal damage (10) but 
there are no reports of hypomagnesaemia resulting from 
nebulized amphotericin B]. 
Although hypomagnesaemia can result from complex 
and interacting factors, aminoglycoside toxicity was the 
most likely cause in this case, damaging the renal tubules 
which subsequently leaked magnesium. We suggest that all 
patients with cystic fibrosis who receive prolonged and/or 
repeated courses of aminoglycosides should have regular 
monitoring of their serum magnesium levels. 
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Cushing’s Disease and tuberculosis 
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Introduction 
Cushing’s Syndrome comprises symptoms and signs caused 
by prolonged exposure to high free plasma glucocorticoid 
levels. Patients have an increased susceptibility to infection, 
and it is felt that the risk of infection correlates with the 
degree of hypercortisolism (1). Consequently, opportunistic 
infection is less likely in patients with pituitary-dependent 
Cushing’s Syndrome than in patients with adrenal 
tumours or ectopic adrenocorticotrophic hormone (ACTH) 
production, who tend to have much higher cortisol 
secretion rates (1). 
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Case Report 
A 40-year-old Caucasian woman was admitted with a right 
femoral deep vein thrombosis (DVT), having developed 
severe proximal myopathy necessitating the use of a wheel- 
chair for the previous 4 months. Over the past 2 years, she 
had repeatedly failed to attend further investigations for 
new onset amenorrhoea and hypertension, the latter treated 
with a thiazide diuretic. She smoked 30 cigarettes per day 
but did not drink to excess. On physical examination, she 
had the classical signs of Cushing’s Syndrome including 
moon face, truncal obesity, buffalo hump, thin skin, easy 
bruising, wide purple striae, muscular weakness, acne, 
sweating, hirsutism and emotional lability (Plate 1). In 
addition, she had a large patch of fat necrosis over the 
lower abdomen leaking serous fluid and a 3 x 5 cm abscess 
in the right popliteal fossa, both present over the last 2 
